Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. announced a corporate name change to "Tevogen Inc.", effective July 30, 2026. This change was formalized through a certificate of amendment to its Certificate of Incorporation and a corresponding amendment to its Bylaws. The company confirmed that the name change will not impact the rights of its security holders, nor will it alter the ticker symbols (TVGN and TVGNW) or CUSIP numbers for its common stock and public warrants.

Tevogen Bio Holdings Inc. announced that its 2026 Annual Meeting of Stockholders will be held virtually on Monday, August 24, 2026. Stockholders of record as of July 23, 2026, will be entitled to vote. The company also set deadlines for stockholder proposals and director nominations, requiring them to be submitted by July 23, 2026, to be considered timely.

Tevogen Bio Holdings Inc. announced the formation of a new healthcare services initiative, led on an interim basis by William Keane, Vice President of Strategic Initiatives. This initiative includes the evaluation of potential acquisitions of a Management Services Organization (MSO) and a Contract Research Organization (CRO). These acquisitions are projected to generate approximately $100 million in combined annual revenue, supporting the company's evolution into a broader healthcare enterprise and its mission to enhance affordability and access.

Tevogen Bio Holdings Inc. announced continued progress on strategic acquisition initiatives aimed at achieving long-term financial self-sufficiency and generating approximately $100 million in combined annual revenue. These initiatives include evaluating a contract research organization (CRO) and other opportunities to expand its broader healthcare platform. The company seeks to evolve into a revenue-generating enterprise comprising its biotechnology, AI, and potential healthcare services arms, with a focus on capital discipline and long-term value creation.

Tevogen Bio Holdings Inc. announced a non-binding Letter of Intent to evaluate a potential transaction with a Management Services Organization (MSO). This proposed deal, along with other strategic acquisition initiatives, is anticipated to expand Tevogen's healthcare infrastructure and could pave the way for approximately $100 million in combined annual revenue. The transaction remains subject to due diligence, definitive documentation, and customary closing conditions.

Tevogen Bio Holdings Inc. reported significant operational improvements, with loss from operations declining 51% to $26.1 million in full year 2025 from $53.6 million in 2024. This positive trend continued into Q1 2026, with a 48% improvement to $5.4 million. The company also advanced strategic initiatives, including establishing Tevogen.AI and expanding its cell therapy pipeline, while evaluating potential revenue-generating acquisitions and maintaining disciplined capital allocation to protect shareholder equity.

Tevogen Bio Holdings Inc. reported a net loss of $(5.45) million for the first quarter of 2026, a significant improvement from $(10.37) million in the prior year. The company also effected a 1-for-50 reverse stock split in March 2026. Despite reducing operating expenses, Tevogen Bio continues to incur losses and negative cash flows, relying on existing funding and a recent $3.0 million private placement of warrants to the Patel Family in May 2026 to maintain liquidity for the next 12 months. The company is in default on $1.65 million in notes payable.

Tevogen Bio Holdings Inc. announced a Private Investment in Public Equity (PIPE) financing with existing investor The Patel Family, LLP, raising gross proceeds of $3 million. The company intends to use the funds to support ongoing operations, advance strategic growth initiatives, and for general corporate purposes. Tevogen will issue 375,000 prefunded warrants at $8.00 each, representing a 14% premium to the previous day's closing price, with the financing expected to close around May 13, 2026.

Tevogen Bio Holdings Inc. filed an amendment to its 2025 Annual Report on Form 10-K/A to incorporate Part III information, including details on directors, executive officers, corporate governance, executive compensation, and security ownership. This amendment was necessary as the company does not expect to file a definitive proxy statement within the required 120 days. The filing also noted a 1-for-50 reverse stock split effected on March 6, 2026, and provided updated compensation figures for its named executive officers and beneficial ownership data.

Tevogen Bio Holdings Inc. announced significant progress in its artificial intelligence initiative, Tevogen.AI, with its PredicTcell™ training algorithm nearing completion. The proprietary machine learning model, designed to identify immunologically active peptides, has been trained on a large dataset, expanding to over 180 parameters and achieving an approximate 10% improvement in precision. The company is also evaluating potential co-development partnerships and has developed an internal application for the model, laying the groundwork for a future customer-facing platform.